Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Warrants

<< Previous

Bullboard Posts

Next >>

Post by pelabooston Aug 14, 2024 6:27pm

439 Views

Post# 36179454

Warrants

If you look at the first quarter of 2024, there were 8,267.778 common share purchase warrants outstanding. That may not have been mentioned in the second quarter 2024 report.

We need to know the date of the financing for the 3.5 million warrants that appear to have expired.

Cheers

<< Previous

Bullboard Posts

Next >>

Twelve Labs partners with AWS to revolutionize video search with AI